Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
Authors
Keywords
-
Journal
Clinical & Developmental Immunology
Volume 2011, Issue -, Pages 1-16
Publisher
Hindawi Limited
Online
2011-12-27
DOI
10.1155/2011/890758
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Effects of Trastuzumab
- (2012) Marianna Nuti et al. Journal of Cancer
- Signal transduction by vascular endothelial growth factor receptors
- (2011) Sina Koch et al. BIOCHEMICAL JOURNAL
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
- (2011) John Farley et al. GYNECOLOGIC ONCOLOGY
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
- (2011) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Is There a Real Standard For Stage IVa Cervical Cancer?
- (2011) Filippo Bellati et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
- (2011) Alessandro D. Santin et al. GYNECOLOGIC ONCOLOGY
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
- (2011) K. Baumann et al. GYNECOLOGIC ONCOLOGY
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
- (2011) Maurie Markman GYNECOLOGIC ONCOLOGY
- Trastuzumab
- (2011) A. H. Boekhout et al. ONCOLOGIST
- Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients
- (2010) Linda Hertlein et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- MUC1 immunotherapy
- (2010) Richard E Beatson et al. Immunotherapy
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy
- (2010) Filippo Bellati et al. JOURNAL OF CLINICAL ONCOLOGY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
- (2009) D D Meira et al. BRITISH JOURNAL OF CANCER
- Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
- (2009) J.E. Kurtz et al. GYNECOLOGIC ONCOLOGY
- Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
- (2009) J.D. Hurt et al. GYNECOLOGIC ONCOLOGY
- A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group study
- (2009) James V. Fiorica et al. GYNECOLOGIC ONCOLOGY
- Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
- (2009) Filippo Bellati et al. INVESTIGATIONAL NEW DRUGS
- Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
- (2009) Chiara Napoletano et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- (2009) Sharmila Makhija et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer
- (2008) I. Vandenput et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report
- (2008) Joshua P. Kesterson et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
- (2008) Chad A. Hamilton et al. GYNECOLOGIC ONCOLOGY
- Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
- (2008) Leslie M. Randall et al. GYNECOLOGIC ONCOLOGY
- Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer
- (2008) Angèle L.M. Oei et al. INTERNATIONAL JOURNAL OF CANCER
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer
- (2008) Jonathan S. Berek et al. JOURNAL OF IMMUNOTHERAPY
- Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003
- (2008) Peter M. Smith-Jones et al. NUCLEAR MEDICINE AND BIOLOGY
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- (2008) F Stephen Hodi et al. Nature clinical practice. Oncology
- Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
- (2007) N. ARORA et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More